Glycosyn
announced in December 2024 the availability for licensing of its commercial high-titer HMO production strains and IP covering prebiotic, anti-inflammatory and anti-infective uses, with strains validated at large fermentation scale for 2'-FL, LNT, 3'-SL and 6'-SL.
- Country
- United States
strain-licensing
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| food-alt-protein | ✓ | ✓ | ✓ |
Regulatorsfdaefsanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Human milk oligosaccharides (HMOs) | food-alt-protein | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.